ArticleFundamental & clinical pharmacology2026
Alogliptin Delays the Healing of Traumatic Oral Ulcers in the Buccal Mucosa of Wistar Rats.
Article in Fundamental & clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study is to evaluate the influence of alogliptin treatment on the healing process of traumatic oral ulcers.
methodsFour experimental groups were used: control group (GC) and three test groups treated with oral Alogliptin at 1 (GTA1), 3 (GTA3), and 9 mg/kg/day (GTA9). Ulcer diameter, body weight, glycemic index, colony-forming unit (CFU), and discomfort were analyzed. Histological slides were prepared for healing scores, inflammatory cell counts, collagen deposition analysis, and immunohistochemistry.
resultsAlogliptin treatment increased ulcer area (GTA3-7D: 5.2 ± 1.2; GTA9-3D: 11.8 ± 0.8; GTA9-7D: 5.8 ± 1.3; p < 0.001), CFU counts (p = 0.049), and Grimace/discomfort scores (p = 0.02), while reducing body weight gain (p = 0.007) in GTA3 and GTA9 groups. Microscopic analysis revealed higher histopathological scores (p = 0.039), increased mononuclear cells (p = 0.006), reduced polymorphonuclear cells (p < 0.05), and decreased collagen deposition (18.2 ± 2.6; p = 0.031) in GTA9. Lower TLR4 (p = 0.001) and TGF-β (p < 0.001) expression, alongside increased CD31 immunostaining (p < 0.001), were observed in GTA3 and GTA9, as well as reduced TLR2 expression (p = 0.001) in GTA9.
conclusionAlogliptin delays oral ulcer healing by sustaining inflammation, reducing TGF-β expression, and impairing collagen deposition, and may contribute via reduced TLR2/TLR4 expression, increased microbial burden, and decreased TGF-β.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.